India's First mRNA-Based Covid Vaccine Gets DCGI Approval For Phase 2-3 Trials

India's first mRNA-based Covid-19 vaccine on Tuesday got the Drugs Controller General of India (DCGI) nod to move into Phase 2 and 3 trials. According to reports, the Centre informed that the vaccine developed by Gennova Biopharmaceuticals Ltd. was found to be safe, and was given go-ahead for Phase II/III trials.

Leave a Reply

Your email address will not be published. Required fields are marked *